The global oncology biosimilars market is expected to grow at a CAGR of 16.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of cancer cases and the rising demand for cost-effective treatment options. The global oncology biosimilars market by type includes mAb, immunomodulators, hematopoietic agents, and CSF. The mAb segment accounted for the largest share in 2018 due to its high adoption rate in various therapeutic areas such as breast cancer, lung cancer, and prostate cancer. Immunomodulators are expected to witness significant growth during the forecast period owing to their use in various types of cancers such as leukemia and lymphoma. Hematopoietic agents are also anticipated to grow at a significant pace due to their use in treating blood disorders such as anemia or leukemia. CSF is anticipated to witness moderate growth during the forecast period owing its use in treating brain tumors or spinal cord injuries among others   Â. The global oncology biosimilars market by application includes retail pharmacies, hospital pharmacy, and online pharmacy segments. The retail pharmacies segment accounted for the largest share in 2018 due its wide availability across different geographies which makes it more accessible than other segments like hospital pharmacy or online pharmacy segments which are limited only within specific geographies  Â.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of cancer and rising healthcare expenditure are the major factors driving the growth of this market.
- Increasing number of approvals for biosimilar drugs by regulatory authorities is also expected to fuel the growth of this market in near future.
- Lack of awareness about biosimilars among physicians and patients, high cost associated with these drugs, and lack of reimbursement policies are some factors that may hinder the growth rate in near future.
- The global Oncology Biosimilars market is segmented on basis of product type, end user, region, and country.
Industry Growth Insights published a new data on “Oncology Biosimilars Market”. The research report is titled “Oncology Biosimilars Market research by Types (mAb, Immunomodulators, Hematopoietic Agents, G-CSF , Others), By Applications (Retail Pharmacies, Hospital Pharmacy, Online Pharmacy), By Players/Companies Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Biosimilars Market Research Report
By Type
mAb, Immunomodulators, Hematopoietic Agents, G-CSFÂ , Others
By Application
Retail Pharmacies, Hospital Pharmacy, Online Pharmacy
By Companies
Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Biosimilars Market Report Segments:
The global Oncology Biosimilars market is segmented on the basis of:
Types
mAb, Immunomodulators, Hematopoietic Agents, G-CSFÂ , Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacies, Hospital Pharmacy, Online Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celltrion
- Biocon
- Dr. Reddy’s Laboratories
- STADA Arzneimittel AG
- Intas Pharmaceuticals
- Pfizer
- Sandoz International
- Teva Pharmaceutical Industries Ltd
- Apotex
- BIOCAD
Highlights of The Oncology Biosimilars Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- mAb
- Immunomodulators
- Hematopoietic Agents
- G-CSFÂ
- Others
- By Application:
- Retail Pharmacies
- Hospital Pharmacy
- Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Biosimilars Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncology biosimilars are medications that are made to duplicate the action of a particular type of cancer medication. These medications can help patients with cancer fight their disease more effectively by providing them with a new and improved treatment option.
Some of the major players in the oncology biosimilars market are Celltrion, Biocon, Dr. Reddy¢â‚¬â„¢s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD.
The oncology biosimilars market is expected to register a CAGR of 16.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oncology Biosimilars Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oncology Biosimilars Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oncology Biosimilars Market - Supply Chain
4.5. Global Oncology Biosimilars Market Forecast
4.5.1. Oncology Biosimilars Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oncology Biosimilars Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oncology Biosimilars Market Absolute $ Opportunity
5. Global Oncology Biosimilars Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oncology Biosimilars Market Size and Volume Forecast by Type
5.3.1. mAb
5.3.2. Immunomodulators
5.3.3. Hematopoietic Agents
5.3.4. G-CSF
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oncology Biosimilars Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oncology Biosimilars Market Size and Volume Forecast by Application
6.3.1. Retail Pharmacies
6.3.2. Hospital Pharmacy
6.3.3. Online Pharmacy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oncology Biosimilars Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oncology Biosimilars Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oncology Biosimilars Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oncology Biosimilars Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oncology Biosimilars Demand Share Forecast, 2019-2026
9. North America Oncology Biosimilars Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oncology Biosimilars Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oncology Biosimilars Market Size and Volume Forecast by Application
9.4.1. Retail Pharmacies
9.4.2. Hospital Pharmacy
9.4.3. Online Pharmacy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oncology Biosimilars Market Size and Volume Forecast by Type
9.7.1. mAb
9.7.2. Immunomodulators
9.7.3. Hematopoietic Agents
9.7.4. G-CSF
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oncology Biosimilars Demand Share Forecast, 2019-2026
10. Latin America Oncology Biosimilars Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oncology Biosimilars Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oncology Biosimilars Market Size and Volume Forecast by Application
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacy
10.4.3. Online Pharmacy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oncology Biosimilars Market Size and Volume Forecast by Type
10.7.1. mAb
10.7.2. Immunomodulators
10.7.3. Hematopoietic Agents
10.7.4. G-CSF
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oncology Biosimilars Demand Share Forecast, 2019-2026
11. Europe Oncology Biosimilars Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oncology Biosimilars Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oncology Biosimilars Market Size and Volume Forecast by Application
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacy
11.4.3. Online Pharmacy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oncology Biosimilars Market Size and Volume Forecast by Type
11.7.1. mAb
11.7.2. Immunomodulators
11.7.3. Hematopoietic Agents
11.7.4. G-CSF
11.7.5. Others
11.8. Basis Point Share (BPS) Analysi by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oncology Biosimilars Demand Share, 2019-2026
12. Asia Pacific Oncology Biosimilars Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oncology Biosimilars Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oncology Biosimilars Market Size and Volume Forecast by Application
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacy
12.4.3. Online Pharmacy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oncology Biosimilars Market Size and Volume Forecast by Type
12.7.1. mAb
12.7.2. Immunomodulators
12.7.3. Hematopoietic Agents
12.7.4. G-CSF
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oncology Biosimilars Demand Share, 2019-2026
13. Middle East & Africa Oncology Biosimilars Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oncology Biosimilars Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oncology Biosimilars Market Size and Volume Forecast by Application
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacy
13.4.3. Online Pharmacy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oncology Biosimilars Market Size and Volume Forecast by Type
13.7.1. mAb
13.7.2. Immunomodulators
13.7.3. Hematopoietic Agents
13.7.4. G-CSF
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oncology Biosimilars Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oncology Biosimilars Market: Market Share Analysis
14.2. Oncology Biosimilars Distributors and Customers
14.3. Oncology Biosimilars Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Celltrion
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biocon
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Dr. Reddys Laboratories
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. STADA Arzneimittel AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Intas Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sandoz International
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Teva Pharmaceutical Industries Ltd
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Apotex
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. BIOCAD
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook